Literature DB >> 8120143

Characterization of anti-ganglioside antibodies present in normal human plasma.

R K Mizutamari1, H Wiegandt, G A Nores.   

Abstract

Samples of plasma from normal human adults were screened for anti-ganglioside antibodies by HPTLC-immunostaining and enzyme-linked immunosorbent assay (ELISA). All the samples analyzed showed IgM-immunoreactivity to GM1 ganglioside and its related glycolipid GA1. Reactivity to GD1b, GM2 and LM1 was also detected in 85, 80 and 20% of the analyzed samples, respectively. The main immunoreactivity is related to the asialo-ganglioside GA1. Using inhibition by soluble antigen and affinity chromatography techniques it was possible to distinguish two populations of anti-GA1 antibodies. One with high affinity reacting only with GA1, and another with low affinity reacting also with GM1 and GD1b. The antibodies that recognize GM2 are of low affinity and appear to be different from those that react with GA1. We postulate that the anti-GM1/GD1b immunoreactivity present in normal human plasma could be a cross-reaction of antibodies originally directed to a GA1-like carbohydrate structure. Anti-GA1 and anti-GM1 titers were calculated as the reciprocal of the plasma dilution needed to obtain the half maximal antibody binding, a titer definition that we consider more suitable to compare data from different laboratories than those usually employed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120143     DOI: 10.1016/0165-5728(94)90048-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

Review 2.  The origin of anti-GM1 antibodies in neuropathies: the "binding site drift" hypothesis.

Authors:  Pablo H H Lopez; Ricardo D Lardone; Fernando J Irazoqui; Mariana Maccioni; Gustavo A Nores
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 3.  Human B-1 cells take the stage.

Authors:  Thomas L Rothstein; Daniel O Griffin; Nichol E Holodick; Tam D Quach; Hiroaki Kaku
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

4.  Normally occurring human anti-GM1 immunoglobulin M antibodies and the immune response to bacteria.

Authors:  María E Alaniz; Ricardo D Lardone; Silvia L Yudowski; María I Farace; Gustavo A Nores
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

5.  The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.

Authors:  Eugeniy Smorodin; Boris Sergeyev; Kersti Klaamas; Valentin Chuzmarov; Oleg Kurtenkov
Journal:  Int J Med Sci       Date:  2013-09-23       Impact factor: 3.738

6.  Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues.

Authors:  Natacha Zlocowski; Veronica Grupe; Yohana C Garay; Gustavo A Nores; Ricardo D Lardone; Fernando J Irazoqui
Journal:  Sci Rep       Date:  2019-05-30       Impact factor: 4.379

7.  Anti-Chol-1 antigen, GQ1bα, antibodies are associated with Alzheimer's disease.

Authors:  Toshio Ariga; Masaru Kubota; Makoto Nakane; Kenji Oguro; Robert K Yu; Susumu Ando
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

8.  Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

Authors:  Ana M H Vázquez; Nely Rodrèguez-Zhurbenko; Ana M V López
Journal:  Front Oncol       Date:  2012-11-20       Impact factor: 6.244

9.  Individual Restriction Of Fine Specificity Variability In Anti-GM1 IgG Antibodies Associated With Guillain-Barré Syndrome.

Authors:  Ricardo D Lardone; Nobuhiro Yuki; Fernando J Irazoqui; Gustavo A Nores
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

10.  Most of anti-glycolipid IgG-antibodies associated to neurological disorders occur without their IgM counterpart.

Authors:  Ricardo Dante Lardone; Fernando José Irazoqui; Gustavo Alejandro Nores
Journal:  J Biomed Sci       Date:  2019-09-06       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.